ILA Island Pharmaceuticals Limited
Healthcare · Biotechnology
· website
$0.39
52wk 0.31 – 0.63
Overall
41.3
Value
62.5
Growth
0.0
Health
100.0
Quality
0.0
Momentum
31.1
Dividend
—
Price
About Island Pharmaceuticals Limited
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States. The company's lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats. Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Price analytics
Returns
| 1 day | 5.5% |
| 1 week | -3.8% |
| 1 month | -12.5% |
| 3 months | -18.9% |
| 6 months | 4.1% |
| 1 year | -4.9% |
| 3 years | 375.3% |
Risk
| Volatility (1y ann.) | 76.7% |
| Beta vs ASX 200 | 0.10 |
| Sharpe (1y) | 0.25 |
| VaR 95% (1-day) | -6.6% |
| Max drawdown (1y) | -44.7% |
| Off 1-year high | -32.5% |
Technicals
| RSI(14) | 33 |
| vs 50DMA | -10.5% |
| vs 200DMA | -4.9% |
| Trend | Golden cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
62.5
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
0
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
100.0
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
—
Current ratio
100
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
31.1
6-month return vs ASX 200
55
Price vs 200-day average
34
Price vs 50-day average
0
Position in 52-week range
23
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$114.00M
P/E (trailing)
—
P/E (forward)
0.30
EPS (trailing)
-0.04
Dividend yield
—
Payout ratio
0.0%
Beta
0.12
EV / EBITDA
-9.88
Price / Book
8.56
ROE
-95.5%
Operating margin
-2,240.5%
Net margin
0.0%
Total cash
$12.87M
Total debt
$0
Current ratio
24.62
Debt / Equity
—
Free cash flow
$-2.09M
Avg volume
283,677
Latest annual results
(FY ending 30 Jun 2026)
- Revenue$282.66K
- Gross profit$282.66K
- Operating income-$10.33M
- Net income-$9.84M
- Diluted EPS—
- Free cash flow-$5.68M
- Net debt-$12.87M